Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent application rule struck down by appeals court

Executive Summary

The Federal Circuit appeals court found that the Patent and Trademark Office's rule limiting the number of continuation applications a patent applicant may file conflicts with current law and is thus invalid. But it found that three other PTO rules limiting requests for continued examination and requiring an examination support document for certain filings are within the scope of PTO's rulemaking authority. Inventor Triantafyllos Tafas and GlaxoSmithKline challenged the rules in separate lawsuits, and they had won on all four rules in the district court (1"The Pink Sheet" DAILY, April 1, 2008). The district court must now reconsider the other rules in more detail

You may also be interested in...

Court Nullifies PTO Rules To Limit Patent Filings

Patent office lacks legal authority to make substantive changes to the law, district court says.

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

Stakeholders To Have Say On Future Medicines Verification System In UK

The UK government says it will begin a consultation on a future falsified medicines scheme for Great Britain within a year after the passage of new legislation on medicines and medical devices. Moves are also under way to ensure the smooth supply of medicines from GB to Cyprus, Ireland, Malta and Northern Ireland.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts